Anaptysbio Inc SEC Filings

ANAPTYSBIO, Inc. (ANAB) director John A. Orwin received a grant of 1,300 restricted stock units (RSUs) reported on Form 4 with a transaction date of 09/15/2025. Each RSU represents a contingent right to one share of common stock to be settled for no consideration. The filing shows 10,665 shares beneficially owned by Mr. Orwin following the reported transaction. The RSUs are subject to a time-based vesting schedule stated in the filing: one‑third vested on 09/15/2024, one‑third on 09/15/2025 and the final one‑third on 09/15/2026, each tranche conditioned on continued service. The Form 4 was signed by an attorney‑in‑fact on 09/17/2025.

Renton Hollings, a director of AnaptysBio (ANAB), exercised options and sold shares under a Rule 10b5-1 plan. On 08/08/2025 he exercised options with an exercise price of $6.93 to acquire 10,231 shares and sold portions of those shares: 3,110 sold at a weighted-average price of $19.44 (sales ranged $19.375–$19.46) and 7,121 sold at a weighted-average price of $19.696 (sales ranged $19.48–$20.46). The sales were effected pursuant to a 10b5-1 trading plan adopted March 14, 2024.

Additional details: the exercised options include a 2015 grant that is fully vested and exercisable through its expiration on August 13, 2025. The filing notes remaining options to purchase 10,231 shares referenced in Table II and additional options to purchase up to an aggregate of 101,820 shares. The Form 4 was filed with a signature dated 08/12/2025 by an attorney-in-fact.

AnaptysBio, Inc. (ANAB) Form 144 shows an intended sale of 10,231 common shares with an aggregate market value of $200,712.78 to be executed on or about 08/08/2025 through Morgan Stanley Smith Barney on NASDAQ. The filing states these shares were acquired by a stock option exercise on 08/08/2025 with payment in cash. The notice also discloses prior sales by the same person, HOLLINGS C RENTON: 20,925 shares sold 07/02/2025 for $493,189.70 and 3,015 shares sold 06/18/2025 for $72,269.55. The signer represents there is no undisclosed material adverse information.

AnaptysBio is registering 1,650,000 additional shares of its common stock to be available under the Amended and Restated 2017 Equity Incentive Plan following stockholder approval. The filing makes those shares available for future awards to employees and directors and incorporates prior S-8 registrations and related company filings on file with the SEC.

Morgan Stanley and its subsidiary Morgan Stanley Capital Services LLC filed a Schedule 13G on 08/05/2025 disclosing a combined passive stake of 1,845,002 ANAB shares (6.3 % of outstanding) as of 06/30/2025. The parent company reports shared voting power over 1,841,919 shares and shared dispositive power over 1,845,002 shares; it holds no sole voting or dispositive authority.

The subsidiary individually owns 1,525,502 shares (5.2 %) with fully shared voting and dispositive power. The filing is made under Rule 13d-1(b), classifying Morgan Stanley as a parent holding company/control person (HC, CO) and the subsidiary as a broker-dealer (BD, CO). Both certify the shares were acquired in the ordinary course of business and not for the purpose of influencing control of AnaptysBio.